United States Patent 8,137,994: Claim Scope, Patent Landscape, Exclusivity, and Generic Risk

U.S. Patent No. 8,137,994 protects a patient-selection and treatment protocol for metabolic disease using dopamine agonists, with bromocriptine as the expressly claimed drug. The patent does not claim bromocriptine as a molecule. Its coverage depends on identifying a patient through specified neurochemical or metabolic markers and then administering dopamine agonist therapy.

The strongest commercial relevance is to bromocriptine products marketed for Type 2 diabetes and related metabolic disorders, particularly Cycloset. The patent is narrower than a composition-of-matter patent but can create method-of-use risk for generic labels, promotional activity, clinical protocols, and reimbursement programs that use the claimed patient-selection criteria.

What does U.S. Patent 8,137,994 claim?

The patent contains four claims directed to biomarker-based patient selection and treatment.

Claim	Protected subject matter	Key limitations
1	Patient identification for dopamine agonist therapy	Plasma or urine analysis for catecholamines, metabolites, serotonin markers, dopamine markers, or fasting triglycerides
2	Patient subgroup	Claim 1 patient also has specified metabolic or cardiovascular conditions
3	Treatment method	Identification under claim 1 followed by effective dopamine agonist therapy for a metabolic condition
4	Bromocriptine treatment	Claim 2 patient treated with bromocriptine under a pharmaceutically effective regimen

The patent is therefore a method-of-treatment and patient-stratification patent. It does not cover every use of bromocriptine, every dopamine agonist, or every patient with diabetes.

How does claim 1 define the biomarker threshold?

Claim 1 uses alternative qualifying criteria. A patient can fall within the claim if one or more of the following conditions is met:

Norepinephrine metabolites are more than approximately 30% above normal.
The ratio of norepinephrine or norepinephrine metabolites to dopamine or dopamine metabolites is more than approximately 30% above normal.
Norepinephrine and serotonin are each elevated.
Norepinephrine or norepinephrine metabolites and serotonin are elevated.
Norepinephrine and serotonin metabolites are elevated.
Norepinephrine or norepinephrine metabolites and serotonin metabolites are elevated.
Norepinephrine itself is more than approximately 30% above normal.
Dopamine or dopamine metabolites are more than approximately 30% below normal.
The patient has hypertriglyceridemia and/or hypertension.

The claim language uses “about 30%,” which introduces a claim-construction issue. A court would assess the permitted variation around the 30% threshold using the specification, prosecution history, ordinary technical meaning, and evidence concerning measurement variability.

What patient conditions are covered by claim 2?

Claim 2 adds one or more of the following conditions:

Cardiovascular disease
Type 2 diabetes
Pre-diabetes
Metabolic Syndrome
Obesity
Hyperglycemia
Glucose intolerance
Hyperinsulinemia
Insulin resistance
Elevated plasma lipid levels

Claim 2 depends on claim 1. A patient must satisfy both the claim 1 identification criteria and the additional disease-condition requirement.

What does claim 3 protect?

Claim 3 covers a two-step treatment method:

Identify the patient under claim 1.
Administer an effective dopamine agonist regimen to a patient with one of the listed metabolic conditions.

The claim is broader than claim 4 because it does not limit the therapy to bromocriptine. A competing dopamine agonist could theoretically fall within claim 3 if the other limitations are met.

The claim also creates an evidentiary issue. Infringement may depend on whether the accused treatment program actually performs, directs, or relies on the claimed identification step. Routine prescribing of a dopamine agonist without the claimed testing or patient-selection process presents a different infringement profile from a protocol that orders catecholamine testing and uses the results to select patients.

What does claim 4 add for bromocriptine?

Claim 4 narrows the treatment to bromocriptine. Bromocriptine is the most commercially important compound covered by the patent because VeroScience and its partners developed bromocriptine mesylate for metabolic use, including Type 2 diabetes.

Claim 4 does not cover every bromocriptine prescription. The patient must still satisfy the inherited claim limitations, including the claim 2 disease and biomarker requirements. A generic bromocriptine product used for Parkinson’s disease, hyperprolactinemia, or another non-metabolic indication would not automatically practice claim 4.

What is the patent’s legal scope?

The patent’s scope is best characterized as a layered combination of:

Patient testing
Neurotransmitter or metabolite abnormalities
Metabolic or cardiovascular disease
Dopamine agonist treatment
Bromocriptine treatment for the narrowest claim

A party generally must practice all material limitations of an asserted claim. The patent does not give its owner a monopoly over dopamine agonist therapy in the abstract.

Direct infringement risks

Potentially relevant conduct includes:

Ordering or interpreting plasma or urine testing for the claimed analytes
Selecting patients for dopamine agonist treatment based on the claimed thresholds
Using hypertension or hypertriglyceridemia as a selection criterion
Treating selected patients with bromocriptine
Operating a clinical protocol that combines biomarker testing and dopamine agonist administration
Marketing a product with instructions that encourage the claimed selection and treatment sequence

The risk is lower where a product label contains no biomarker-selection instruction and the manufacturer does not promote such use. The risk increases where a label, treatment algorithm, clinical support service, or sales message directs clinicians to identify patients using the claimed criteria.

Indirect infringement and induced use

Induced-infringement exposure would depend on evidence that a manufacturer knowingly encouraged acts constituting infringement. Relevant evidence could include:

Promotional materials
Dosing algorithms
Medical-affairs communications
Patient-selection tools
Clinical-trial protocols
Reimbursement criteria
Instructions for use

A generic manufacturer that files a Paragraph IV certification and removes patented use information through a proper section viii statement may reduce, but not necessarily eliminate, method-of-use exposure. Actual prescribing and promotional conduct remain important.

When does U.S. Patent 8,137,994 lose exclusivity?

The patent issued on March 20, 2012. Its enforceable term is not determined by the issue date. Under 35 U.S.C. § 154, the term generally runs 20 years from the earliest effective U.S. nonprovisional filing date in the relevant priority chain, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.

Event	Date or rule
Patent issued	March 20, 2012
General term rule	20 years from earliest effective nonprovisional U.S. filing
Patent-term adjustment	Must be taken from the USPTO patent record
Patent-term extension under 35 U.S.C. § 156	Not established from the claim text
Terminal disclaimer	Must be checked in the continuity and prosecution records
Post-expiration enforcement	No ordinary infringement liability for acts occurring after expiration

The critical date for commercial planning is the USPTO-calculated expiration date shown in Patent Center or the patent face. The grant date alone cannot be used to calculate expiration. Any freedom-to-operate analysis should distinguish this patent’s term from FDA regulatory exclusivity and from other bromocriptine patents.

Is U.S. Patent 8,137,994 listed in the Orange Book?

Orange Book listing is product-specific. A patent may be relevant to a branded product without being listed for every dosage form or indication.

Cycloset, bromocriptine mesylate, is an FDA-approved product for improving glycemic control in adults with Type 2 diabetes as an adjunct to diet and exercise. The FDA Orange Book must be reviewed for:

NDA 022283
Listed patent numbers
Patent-use codes
Pediatric exclusivity
The listed product strength and dosage form
Any delisting or expiration updates

A method-of-use patent can be listed if it claims an approved method of using the drug. Listing does not prove that every generic use infringes. It does, however, affect ANDA certification obligations and may trigger the statutory 30-month stay if the patent holder files a timely infringement action after receiving a Paragraph IV notice.

The Orange Book and Drugs@FDA records should be treated as the controlling sources for current listing status, rather than commercial patent databases alone. [1][2]

What FDA regulatory status is relevant to the patent?

Bromocriptine has multiple regulatory identities:

Product or use	Regulatory relevance
Cycloset	Bromocriptine mesylate for glycemic control in Type 2 diabetes
Parlodel	Bromocriptine product historically used for hyperprolactinemia, Parkinson’s disease, and other indications
Generic bromocriptine tablets	May be approved for indications that do not correspond to Cycloset’s metabolic-use labeling
Dopamine agonists generally	Class members such as cabergoline, pramipexole, and ropinirole are not automatically covered by the bromocriptine-specific claim

FDA approval does not itself establish patent infringement. The relevant question is whether the approved indication, labeling, manufacturing, promotion, or actual use meets every claim limitation.

What patents protect bromocriptine metabolic therapy?

The relevant patent estate should be divided into four groups:

Patent category	Business significance
Patient-selection patents	Protect identifying patients using neurotransmitter, metabolite, triglyceride, or blood-pressure criteria
Method-of-use patents	Protect administering dopamine agonists for diabetes or metabolic disease
Formulation patents	Protect dosage form, release profile, excipients, or pharmacokinetic design
Manufacturing patents	Protect synthesis, purification, salt formation, or tablet production

U.S. Patent 8,137,994 is primarily a patient-selection and method-of-treatment patent. It is not a broad formulation patent and does not claim a new bromocriptine chemical entity.

The Cycloset commercial product also creates a formulation and product-development question. A generic applicant may seek approval for bromocriptine tablets through an ANDA, while a sponsor developing a distinct dosage form may pursue a 505(b)(2) application. The patent risk depends on the formulation claims, the approved labeling, and the product’s intended use.

How strong is the patent estate?

The patent has moderate strategic value but limited breadth compared with a composition-of-matter patent.

Strengths

It covers a defined patient-selection framework.
Claim 3 reaches dopamine agonists beyond bromocriptine.
Claim 4 directly targets bromocriptine treatment.
The claimed conditions include common metabolic diseases.
Hypertriglyceridemia and hypertension provide alternative patient-selection routes that do not require the full neurotransmitter panel.

Weaknesses

The claims depend on clinical and laboratory facts that may not be recorded consistently.
“About 30%” may create factual disputes over measurement tolerance and normal ranges.
Normal levels may vary by laboratory, specimen type, fasting status, assay, and patient population.
Claim 3 requires both identification and treatment.
Claim 4 is limited to bromocriptine and inherits claim 2’s disease limitations.
The patent does not block bromocriptine products used for unrelated indications.
A generic label may omit patented use information if the FDA permits a legally effective carve-out.

The patent is stronger against a deliberately designed biomarker-guided metabolic-treatment program than against ordinary prescription of bromocriptine based only on an FDA-approved diabetes indication.

Which companies are potential challengers?

The relevant challenger groups are:

Generic bromocriptine manufacturers seeking ANDA approval.
Sponsors developing alternative dopamine agonists for metabolic disease.
Companies developing bromocriptine formulations with different release characteristics.
Digital-health or specialty-pharmacy businesses using algorithmic patient selection.
Manufacturers of products approved for non-metabolic bromocriptine indications.

A Paragraph IV challenge would require the applicant to assert that the patent is invalid, unenforceable, or not infringed. Common grounds could include:

Anticipation
Obviousness
Lack of written description
Lack of enablement
Indefiniteness
Noninfringement based on omission of the identification step
Noninfringement based on a carved-out label

The biomarker combinations and disease-selection framework would likely make claim construction and obviousness central issues. Prior art concerning dopamine agonists, circadian neuroendocrine regulation, insulin resistance, hypertension, and metabolic syndrome would be particularly relevant.

What litigation and settlement issues matter?

A patent-holder response to a Paragraph IV notice could produce:

Hatch-Waxman litigation
A 30-month FDA approval stay
A settlement restricting launch timing
A license with a royalty or milestone structure
A covenant not to sue for carved-out indications
A no-authorized-generic arrangement
A launch-at-risk decision by the ANDA filer

The public record for a particular patent should be checked through PACER, the FDA Orange Book, and USPTO Patent Center. Patent litigation status can change independently of the patent’s validity and enforceability.

A settlement involving one generic applicant would not automatically grant freedom to all other applicants. Each applicant’s label, formulation, certification, and litigation posture must be analyzed separately.

How does this patent compare with competing dopamine agonist patents?

Issue	U.S. 8,137,994	Typical composition patent	Typical formulation patent
Protected subject	Patient selection and treatment	Active ingredient	Dosage form or release profile
Breadth	Narrow to defined clinical criteria	Potentially very broad	Product-specific
Dependence on actual use	High	Lower	Moderate
Relevance to bromocriptine	Direct	May not exist for old molecule	Depends on product
Generic vulnerability	Label and prescribing dependent	Usually high until expiry	Product-design dependent
Evidence required	Testing, diagnosis, selection, treatment	Product identity	Formulation composition or performance

Cabergoline, pramipexole, ropinirole, and other dopamine agonists do not automatically infringe. Claim 3 could present risk for another dopamine agonist only if the accused therapy uses the claimed patient-identification process and treats the specified metabolic condition.

What generic launch scenarios exist?

Scenario 1: Non-metabolic bromocriptine launch

A generic applicant launches for approved non-metabolic indications and excludes the patented metabolic use. Risk is comparatively limited if the label, promotion, and distribution practices do not encourage claim 4 conduct.

Scenario 2: Full metabolic indication

A generic seeks approval for the same metabolic indication as Cycloset. This creates the highest risk of Paragraph IV litigation and a potential 30-month stay.

Scenario 3: Label carve-out

The applicant removes the patented method from its labeling under section viii. The outcome depends on whether the remaining label and foreseeable promoted use still encourage the patented method.

Scenario 4: Launch after patent expiry

Once the patent term ends, the patent no longer blocks the claimed method. Other unexpired patents, regulatory exclusivity, trademarks, and formulation rights may still affect launch.

What are the geographic and manufacturing barriers?

The patent is a U.S. right. It does not directly control:

European bromocriptine use
Canadian products
Japanese products
Manufacturing outside the United States for non-U.S. markets
Foreign clinical protocols

U.S. manufacturing can create infringement exposure under 35 U.S.C. § 271(a). Importation of a product made by a patented process can implicate § 271(g), although the claims here are primarily directed to treatment and patient identification rather than a manufacturing process.

The principal manufacturing barrier is therefore indirect. A manufacturer may need to separate a non-infringing product label, medical-information program, and distribution strategy from a patented metabolic-use protocol.

Key Takeaways

U.S. Patent 8,137,994 is a biomarker-based patient-selection and treatment patent, not a bromocriptine composition patent.
Claim 1 covers specified norepinephrine, dopamine, serotonin, metabolite, triglyceride, and hypertension criteria.
Claim 3 extends to dopamine agonist therapy for listed metabolic conditions.
Claim 4 narrows the treatment to bromocriptine.
The main infringement risk arises when a product or clinical program actively identifies patients using the claimed criteria and then administers dopamine agonist therapy.
Ordinary bromocriptine use outside the claimed metabolic-selection protocol is not automatically covered.
Orange Book status must be assessed against the specific FDA product, NDA, patent-use code, and current listing record.
Generic risk depends on the ANDA label, Paragraph IV or section viii strategy, promotional conduct, and other unexpired patents.
The patent’s exact enforceable expiration date must be taken from the USPTO continuity, patent-term-adjustment, and terminal-disclaimer records rather than inferred from the March 20, 2012 grant date.
The commercial estate should be analyzed together with Cycloset formulation patents, method-of-use patents, FDA exclusivity, and any active Hatch-Waxman litigation.

FAQs

Does U.S. Patent 8,137,994 cover all bromocriptine products?

No. It covers specified patient-identification and metabolic-treatment methods involving bromocriptine. It does not cover bromocriptine as a molecule or every approved bromocriptine indication.

Can a generic bromocriptine company avoid the patent by omitting biomarker testing?

Potentially, but omission from the label does not resolve all risk. Actual promotional conduct, clinical-support programs, and induced use must also be evaluated.

Does hypertension alone satisfy the patient-selection requirement?

Claim 1 expressly includes hypertension and/or hypertriglyceridemia as alternative qualifying conditions. The remaining claim limitations still apply to dependent claims.

Are cabergoline and pramipexole covered by claim 4?

No. Claim 4 is limited to bromocriptine. Claim 3 is broader, but another dopamine agonist would need to be administered within the claimed patient-identification and metabolic-treatment framework.

Does FDA approval of Cycloset prove that the patent is valid?

No. FDA approval and patent validity are separate legal questions. FDA approval establishes regulatory authorization, while validity depends on patent-law requirements and any court or Patent Trial and Appeal Board determination.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2009). Cycloset: Prescribing information. NDA 022283.
U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,137,994, methods of identifying patients to be treated by dopamine agonist therapy. Washington, DC.
35 U.S.C. §§ 154, 271, 271(e).
21 U.S.C. § 355(j).
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

Details for Patent: 8,137,994

Summary for Patent: 8,137,994